Ben E Biesterveld1, Shannon M Koehler2, Nathan P Heinzerling3, Rebecca M Rentea3, Katherine Fredrich1, Scott R Welak4, David M Gourlay5. 1. Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Division of Pediatric Surgery, Department of Surgery, Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 3. Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. Division of Neonatology, Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, Wisconsin; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin. 5. Division of Pediatric Surgery, Department of Surgery, Children's Hospital of Wisconsin, Milwaukee, Wisconsin; Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: dgourlay@chw.org.
Abstract
BACKGROUND: Intestinal alkaline phosphatase (IAP) activity is decreased in necrotizing enterocolitis (NEC), and IAP supplementation prevents NEC development. It is not known if IAP given after NEC onset can reverse the course of the disease. We hypothesized that enteral IAP given after NEC induction would not reverse intestinal injury. MATERIALS AND METHODS: NEC was induced in Sprague-Dawley pups by delivery preterm followed by formula feedings with lipopolysaccharide (LPS) and hypoxia exposure and continued up to 4 d. IAP was added to feeds on day 2 until being sacrificed on day 4. NEC severity was scored based on hematoxylin and eosin-stained terminal ileum sections, and AP activity was measured using a colorimetric assay. IAP and interleukin-6 expression were measured using real time polymerase chain reaction. RESULTS: NEC pups' alkaline phosphatase (AP) activity was decreased to 0.18 U/mg compared with controls of 0.57 U/mg (P < 0.01). Discontinuation of LPS and hypoxia after 2 d increased AP activity to 0.36 U/mg (P < 0.01). IAP supplementation in matched groups did not impact total AP activity or expression. Discontinuing LPS and hypoxia after NEC onset improved intestinal injury scores to 1.14 compared with continued stressors, score 2.25 (P < 0.01). IAP supplementation decreased interleukin-6 expression two-fold (P < 0.05), though did not reverse NEC intestinal damage (P = 0.5). CONCLUSIONS: This is the first work to demonstrate that removing the source of NEC improves intestinal damage and increases AP activity. When used as a rescue treatment, IAP decreased intestinal inflammation though did not impact injury making it likely that IAP is best used preventatively to those neonates at risk.
BACKGROUND:Intestinal alkaline phosphatase (IAP) activity is decreased in necrotizing enterocolitis (NEC), and IAP supplementation prevents NEC development. It is not known if IAP given after NEC onset can reverse the course of the disease. We hypothesized that enteral IAP given after NEC induction would not reverse intestinal injury. MATERIALS AND METHODS: NEC was induced in Sprague-Dawley pups by delivery preterm followed by formula feedings with lipopolysaccharide (LPS) and hypoxia exposure and continued up to 4 d. IAP was added to feeds on day 2 until being sacrificed on day 4. NEC severity was scored based on hematoxylin and eosin-stained terminal ileum sections, and AP activity was measured using a colorimetric assay. IAP and interleukin-6 expression were measured using real time polymerase chain reaction. RESULTS: NEC pups' alkaline phosphatase (AP) activity was decreased to 0.18 U/mg compared with controls of 0.57 U/mg (P < 0.01). Discontinuation of LPS and hypoxia after 2 d increased AP activity to 0.36 U/mg (P < 0.01). IAP supplementation in matched groups did not impact total AP activity or expression. Discontinuing LPS and hypoxia after NEC onset improved intestinal injury scores to 1.14 compared with continued stressors, score 2.25 (P < 0.01). IAP supplementation decreased interleukin-6 expression two-fold (P < 0.05), though did not reverse NEC intestinal damage (P = 0.5). CONCLUSIONS: This is the first work to demonstrate that removing the source of NEC improves intestinal damage and increases AP activity. When used as a rescue treatment, IAP decreased intestinal inflammation though did not impact injury making it likely that IAP is best used preventatively to those neonates at risk.
Authors: Rebecca Maria Rentea; Scott R Welak; Katherine Fredrich; Deborah Donohoe; Kirkwood A Pritchard; Keith T Oldham; David M Gourlay; Jennifer L Liedel Journal: Eur J Pediatr Surg Date: 2012-11-19 Impact factor: 2.191
Authors: Rebecca M Rentea; Jennifer L Liedel; Katherine Fredrich; Scott R Welak; Kirkwood A Pritchard; Keith T Oldham; Pippa M Simpson; David M Gourlay Journal: J Surg Res Date: 2012-06-01 Impact factor: 2.192
Authors: Kathryn T Chen; Madhu S Malo; Laura Kline Beasley-Topliffe; Klaas Poelstra; Jose Luis Millan; Golam Mostafa; Sayeda N Alam; Sundaram Ramasamy; H Shaw Warren; Elizabeth L Hohmann; Richard A Hodin Journal: Dig Dis Sci Date: 2010-09-16 Impact factor: 3.199
Authors: Cynthia L Leaphart; Jaime Cavallo; Steven C Gribar; Selma Cetin; Jun Li; Maria F Branca; Theresa D Dubowski; Chhinder P Sodhi; David J Hackam Journal: J Immunol Date: 2007-10-01 Impact factor: 5.422
Authors: Kevin M Riggle; Rebecca M Rentea; Scott R Welak; Kirkwood A Pritchard; Keith T Oldham; David M Gourlay Journal: J Surg Res Date: 2012-11-08 Impact factor: 2.192
Authors: Scott O Guthrie; Phillip V Gordon; Victor Thomas; James A Thorp; Joyce Peabody; Reese H Clark Journal: J Perinatol Date: 2003-06 Impact factor: 2.521
Authors: Angela K Moss; Sulaiman R Hamarneh; Mussa M Rafat Mohamed; Sundaram Ramasamy; Halim Yammine; Palak Patel; Kanakaraju Kaliannan; Sayeda N Alam; Nur Muhammad; Omeed Moaven; Abeba Teshager; Nondita S Malo; Sonoko Narisawa; José Luis Millán; H Shaw Warren; Elizabeth Hohmann; Madhu S Malo; Richard A Hodin Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-01-10 Impact factor: 4.052
Authors: Florian Kühn; Ruifeng Duan; Matthias Ilmer; Ulrich Wirth; Fatemeh Adiliaghdam; Tobias S Schiergens; Joachim Andrassy; Alexandr V Bazhin; Jens Werner Journal: Visc Med Date: 2021-04-29
Authors: Marianna Parlato; Fabienne Charbit-Henrion; Jie Pan; Claudio Romano; Rémi Duclaux-Loras; Marie-Helene Le Du; Neil Warner; Paola Francalanci; Julie Bruneau; Marc Bras; Mohammed Zarhrate; Bernadette Bègue; Nicolas Guegan; Sabine Rakotobe; Nathalie Kapel; Paola De Angelis; Anne M Griffiths; Karoline Fiedler; Eileen Crowley; Frank Ruemmele; Aleixo M Muise; Nadine Cerf-Bensussan Journal: EMBO Mol Med Date: 2018-04 Impact factor: 12.137